BASEL, Switzerland, Feb. 15 /PRNewswire-FirstCall/ - Neuro-Biotech Corp. (PINKSHEET: MRES) (OTCQB: MRES) is pleased to provide its shareholders additional details about the unsolicited offer received on February 9, 2011. The offer was received from Auric Pharma Science, a well established company based out of Madrid, Spain, that has been operating since 1972. The offer provided is for the purchase of all the outstanding shares of MRES at a price of $0.15 per share.
As announced this morning, management has deemed it in the best interest of the Company to accept such an offer based on the documents provided by Auric. However, there are outstanding conditions that have yet to be met in order to complete the due diligence. Such details should be addressed by end of the day, on February 25, 2011.
For more information on Neuro-Biotech Corp or to contact a company representative, please visit: www.neuro-biotechcorp.com
FORWARD LOOKING STATEMENTS
This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
SOURCE Neuro-Biotech Corp.